Gene polymorphisms and their role in epilepsy treatment and prognosis.
The human genome carries an enormous number of genetic variants, many of them of functional consequence. In epilepsy, they are likely to be involved in drug-specific treatment efficacy, unwanted or even toxic drug reactions, teratogenic risks in pregnancy as well as in the long-term prognosis of patients with epilepsy. As in many other disorders with a complex genetic background, the associated genetic variants that could be verified successfully in replication studies are still only a few. However, new techniques and improved research strategies are likely to increase their number in the foreseeable future, although at a much slower pace as initially expected.
Steinlein
Ortrud K
OK
Institute of Human Genetics, University Hospital, Ludwig-Maximilians-University of Munich, Goethestr. 29, 80336, Munich, Germany. Ortrud.Steinlein@med.uni-muenchen.de
D000014:Abnormalities, Drug-Induced / Q000209:etiology / Q000235:genetics; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004827:Epilepsy / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D015533:Transcriptional Activation / Q000187:drug effects
D000927:Anticonvulsants